HD Biosciences

WuXi AppTec acquires HD Biosciences

Friday, January 20, 2017

WuXi AppTec, a global pharmaceutical, biotechnology and medical device open-access capability and technology platform, has acquired HD Biosciences (HDB), a biology-focused preclinical drug discovery CRO. After completion of acquisition, HD Biosciences will become a wholly-owned subsidiary of WuXi, and will continue to focus on growing its core competences and providing greater services. The acquisition will further strengthen WuXi’s R&D capability from target validation to lead discovery and optimization, improving and expanding WuXi’s open-access enabling service platform.

[Read More]